Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2023 | The role of the FoxO1-Rictor-pAkt axis in CLL & how this impacts response to BCR inhibitors

Laura Ondrisova • 16 Jun 2023
ICML 2023
Chronic Lymphocytic Leukemia Leukemia

Laura Ondrisova, MSc, Central European Institute of Technology, Brno, Czech Republic, discusses research exploring the role of the FoxO1-Rictor-pAkt axis in chronic lymphocytic leukemia (CLL) and how this impacts response to BCR inhibitors. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals